Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2023 | AACR 2023 highlights in PI3Kα and FGFR inhibition

Alison Schram • 18 Apr 2023
AACR 2023
General Pemigatinib RLY-2608
FIGHT-207

Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of her highlights from the 2023 American Association for Cancer Research (AACR) Annual Meeting 2023, including findings from a Phase I trial (NCT05216432) of RLY-2608, a novel PI3Kα inhibitor, in patients with solid tumors. Dr Schram additionally highlights findings from FIGHT-207 trial (NCT03822117) of pemigatinib in FGFR-mutant tumors, as well as novel advances in ATR inhibitors. This interview took place at the AACR Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alison Schram

0:46
eNRGy: zenocutuzumab in NRG1 fusion-positive pancreatic ductal adenocarcinoma
Alison Schram • 21 Oct 2023
1:56
eNRGy: zenocutuzumab in NRG1 fusion-positive NSCLC
Alison Schram • 21 Oct 2023
0:34
Rational for HER3-targeting in NRG1 fusion-positive NSCLC
Alison Schram • 21 Oct 2023
1:31
Optimizing and overcoming resistance to current KRAS inhibitors
Alison Schram • 18 Apr 2023

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals